Akhlesh K. Jain* and Keerti Mishra
Background: Conventional drug delivery agents for life-threatening disease cancer lacks specificity towards cancer cells, results in seriously toxicities to normal cells with a poor therapeutic indices. These toxic side effects often limit dose escalation of anticancer drugs, leading to incomplete tumor suppression/cancer eradication, early disease relapse, and ultimately, the development of drug resistance. Accordingly, targeting of the tumor vasculatures is essential for the treatment of cancer.
Objective: To search and describe a safer drug delivery carrier for the treatment of cancer with reduced systemic toxicities.
Methods: Data were collected from Medline, PubMed, Google Scholar, Science Direct through searching of keywords: ‘liposomes’, ‘nanocarriers’, ‘targeted drug delivery’, ‘ligands’, ‘liposome for anti-cancerous drugs’, ‘treatment for cancer’ and ‘receptor targeting’.
Results: Liposomes have provided a safe platform for the targeted delivery of encapsulated anti-cancer drugs for the treatment of cancer which results in the reduction of the cytotoxic side effects of anti-cancer drugs on normal cells.
Conclusion: Liposomal targeting is a better emerging approach as an advanced drug delivery carrier with targeting ligands for anti-cancer agents.
Cancer, Anticancer drugs, Nanocarriers, Drug delivery, Liposomes, Ligands, Targeted therapy.
School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur- 495 009 (C.G.), School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur- 495 009 (C.G.)